Tag: Pfizer/BioNTech

Posted on

No Surprise ,Pfizer and BioNTech said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant

external content.duckduckgo 35
the staff of the Ridgewood blog
Ridgewood NJ, having only been on the global radar since late November, early analysis around the world regarding the Omicron variant of concern (VOC) is providing insight into its characteristics and risks. Some preliminary laboratory analyses suggest that the Omicron variant could exhibit some resistance to SARS-CoV-2 vaccines. One study conducted by researchers in Germany (preprint) found that blood serum collected from fully vaccinated individuals had reduced efficacy in neutralizing the Omicron variant. The researchers tested sera from a variety of vaccinated patients, including those who received the Moderna, Pfizer-BioNTech, and AstraZeneca-Oxford vaccines, including some with heterologous combinations and some who received booster doses. The researchers observed reductions in neutralizing capacity on the order of 10-30 times, compared to the Delta variant. Additionally, sera from participants who received a heterologous combination of the AstraZeneca-Oxford and Pfizer-BioNTech vaccines exhibited “no efficacy against Omicron.” Preliminary findings from studies conducted by researchers in South Africa and Sweden (both preprint) are similar.

Continue reading No Surprise ,Pfizer and BioNTech said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant

Posted on

Vaccine Makers are Working to Determine how well the Current Vaccine Formulations hold up Against Omicron

external content.duckduckgo 22
the staff of the Ridgewood blog
Ridgewood NJ, the emergence of the Omicron SARS-CoV-2 variant in southern Africa has vaccine manufacturers discussing vaccine effectiveness and the possibility of updating vaccines to make them variant-specific. Omicron has around 50 mutations, and more than 30 of the mutations are located on the viral spike protein that is responsible for entry into host cells. The SARS-CoV-2 spike protein also is one of the primary antibody targets for the immune system. According to some analysis, most of the antibody target sites on Omicron’s spike protein are mutated, and several of those differences could indicate that Omicron is capable of escaping current vaccine formulations. A subset of Omicron’s spike mutations have been previously reported in the Beta and Delta variants, but 26 spike mutations are believed to be unique. Scientists are anticipating a decrease in antibody neutralization of the virus, and doctors in South Africa are reporting reinfections in patients who have already recovered from COVID-19.

Continue reading Vaccine Makers are Working to Determine how well the Current Vaccine Formulations hold up Against Omicron

Posted on

CDC encourages vaccinated individuals to continue taking public health precautions to prevent infection and transmission

external content.duckduckgo 12
the staff of the Ridgewood blog
Ridgewood NJ, on April 2, a team of researchers led by the US CDC COVID-19 Response Team published interim estimates of a prospective cohort study describing the effectiveness of the two-dose Pfizer-BioNTech and Moderna SARS-CoV-2 mRNA vaccines among healthcare and other frontline workers. The report, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), describes data collected from December 14, 2020 to March 13, 2021, through the HEROES-RECOVER network of 8 US sites. Overall, 3,950 frontline workers (i.e., those who routinely are within 3 feet of other individuals as part of their occupation) with no prior laboratory documentation of SARS-CoV-2 infection were included in the analysis. Participants were actively monitored for COVID-19 symptoms and self-collected weekly nasal swabs which were tested for SARS-CoV-2 infection.

Continue reading CDC encourages vaccinated individuals to continue taking public health precautions to prevent infection and transmission

Posted on

Comparing Vaccines, Experts say , “The best vaccine is the one that’s in your arm” 

external content.duckduckgo 35
the staff of the Ridgewood blog
Ridgewood NJ, according to Johns Hopkins Center for Health Security,  as more data become available from Phase 3 clinical vaccine trials, it is natural to compare vaccines’ performance characteristics against each other. For example, the Mayor of Detroit, Michigan, reportedly declined a shipment of the J&J-Janssen vaccine in favor of prioritizing the Pfizer-BioNTech and Moderna vaccines. But unlike many products that have well-established standards and metrics, the clinical trials for each vaccine were designed and implemented independently, which makes direct comparison difficult. The focus on specific efficacy numbers between trials may not provide the whole picture. The relatively small numbers of severe cases and deaths in the clinical trials for all of the vaccines so far make it more difficult to evaluate their efficacy in preventing more severe forms of COVID-19, as a single case could result in major changes to the efficacy estimates.

Continue reading Comparing Vaccines, Experts say , “The best vaccine is the one that’s in your arm” 

Posted on

Delivery for Pfizer/BioNTech COVID-vaccine has Proven Challenging

Vaccine in vial with syringe1

the staff of the Ridgewood blog

Ridgewood NJ, according to Johns Hopkins Center for Health Security the complex cold chain logistics required for the Pfizer/BioNTech SARS-CoV-2 vaccine have proven challenging in certain settings in the first week of the United States’ vaccination operations. While the principal concern in planning for the distribution of this vaccine has been ensuring that the vaccine remains cold enough, incidents in Alabama and California demonstrate that allowing the vaccines to get too cold could also be a risk. Reportedly, several thousand doses of the vaccine shipped to Alabama and California were exposed to temperatures below the acceptable threshold of -112°F (-80°C) while en route to the state distribution centers. The issue was identified before the doses were unloaded from the truck, and the doses were “quarantined” while Pfizer and federal health and regulatory officials determine whether they remain viable. Pfizer shipped replacement doses to both states. These incidents highlight how challenges in implementing cold chain logistics can lead to wastage of vaccine doses, which could be particularly impactful when supply and production capacity are limited.

Continue reading Delivery for Pfizer/BioNTech COVID-vaccine has Proven Challenging